Inspire Medical Systems, Inc. (NYSE:INSP) Given Average Recommendation of “Hold” by Brokerages

Inspire Medical Systems, Inc. (NYSE:INSP) has been given a consensus rating of “Hold” by the nineteen brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $138.4706.

INSP has been the subject of a number of research analyst reports. Wolfe Research raised Inspire Medical Systems from a “peer perform” rating to an “outperform” rating and set a $180.00 target price for the company in a research report on Tuesday, November 25th. Oppenheimer cut Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a research note on Thursday. Wells Fargo & Company lowered their target price on Inspire Medical Systems from $160.00 to $145.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 14th. KeyCorp reiterated a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, November 4th. Finally, Stifel Nicolaus set a $110.00 price target on shares of Inspire Medical Systems and gave the company a “buy” rating in a research note on Monday, November 24th.

Insider Activity at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 2,000 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.48, for a total transaction of $254,960.00. Following the completion of the sale, the director directly owned 26,046 shares of the company’s stock, valued at $3,320,344.08. The trade was a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 4.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Inspire Medical Systems

A number of hedge funds have recently added to or reduced their stakes in the stock. V Square Quantitative Management LLC bought a new position in shares of Inspire Medical Systems during the 4th quarter worth approximately $40,000. Manning & Napier Advisors LLC purchased a new stake in shares of Inspire Medical Systems during the third quarter valued at approximately $32,000. Daiwa Securities Group Inc. lifted its holdings in Inspire Medical Systems by 38.7% during the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock worth $60,000 after acquiring an additional 130 shares during the period. Farther Finance Advisors LLC boosted its position in Inspire Medical Systems by 14.6% in the second quarter. Farther Finance Advisors LLC now owns 603 shares of the company’s stock worth $78,000 after purchasing an additional 77 shares during the last quarter. Finally, Larson Financial Group LLC boosted its position in Inspire Medical Systems by 21,266.7% in the third quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock worth $48,000 after purchasing an additional 638 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Inspire Medical Systems Stock Down 1.8%

Inspire Medical Systems stock opened at $79.34 on Friday. The company has a market capitalization of $2.31 billion, a PE ratio of 53.97, a PEG ratio of 8.10 and a beta of 0.72. The firm’s fifty day moving average is $106.07 and its 200 day moving average is $97.14. Inspire Medical Systems has a 12-month low of $70.77 and a 12-month high of $203.12.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.53. Inspire Medical Systems had a net margin of 5.05% and a return on equity of 9.41%. The firm had revenue of $224.50 million during the quarter, compared to the consensus estimate of $220.39 million. During the same period in the previous year, the firm posted $0.60 earnings per share. The business’s revenue was up 10.5% compared to the same quarter last year. Sell-side analysts expect that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Key Headlines Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Wells Fargo remains constructive, saying the company has long-term upside despite short-term reimbursement headwinds; the note provides some support that institutional investors view the issues as near-term. Read More.
• Positive Sentiment: Zacks argues investors should retain INSP, citing traction for the Inspire V device and management’s focus on balancing growth and near-term pressures — a counterpoint to the negative headlines. Read More.
• Neutral Sentiment: Truist downgraded INSP from Buy to Hold with a $96 price target, which still implies upside but signals reduced near-term conviction from that analyst. Read More.
• Neutral Sentiment: Oppenheimer lowered its rating from Outperform to Market Perform after the reimbursement concerns surfaced — another sign of cooling analyst enthusiasm even if not a full negative thesis. Read More.
• Negative Sentiment: CMS removed coverage for certain sleep-apnea therapy related to Inspire’s offering, a direct hit to expected reimbursement that materially increases near-term revenue risk and drove heavy selling pressure. Read More.
• Negative Sentiment: The Law Offices of Frank R. Cruz has opened an investigation into the company and board over disclosures and delays tied to the Inspire V launch, raising the possibility of shareholder litigation and related distraction/costs. Read More.
• Negative Sentiment: Mainstream coverage summarizes the sell-off and links it to the CMS decision, analyst downgrades, and litigation risk — broadening negative sentiment among retail and institutional holders. Read More.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.